|
| 36350094 | How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT). | Clin Pharmacol Ther | 2023 |
| 38082299 | Pharmacogenetic testing and monitoring of complete blood counts among Veterans newly prescribed thiopurine treatments: a retrospective cohort study. | J Pharm Policy Pract | 2023 |
| 37961335 | <i>CYP2C19</i> Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million Veterans Program. | medRxiv | 2023 |
| 37303270 | An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. | Clin Pharmacol Ther | 2023 |
| 34562070 | Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. | Clin Transl Sci | 2022 |
| 35568931 | Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. | Implement Sci Commun | 2022 |
| 35684976 | Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. | Clin Transl Sci | 2022 |
| 36443877 | Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population. | J Transl Med | 2022 |
| 36107166 | Impact of integrating genomic data into the electronic health record on genetics care delivery. | Genet Med | 2022 |
| 35865463 | Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing <i>DPYD</i> and <i>UGT1A1</i> Screening to Guide Chemotherapy Dosing. | Front Oncol | 2022 |
| 34984913 | Attitudes toward pharmacogenetics in patients undergoing <i>CYP2C19</i> testing following percutaneous coronary intervention. | Per Med | 2022 |
| 35319502 | Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs. | Pain | 2022 |
| 35156424 | <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. | J Am Heart Assoc | 2022 |
| 35152405 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. | Clin Pharmacol Ther | 2022 |
| 34881641 | Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions. | Per Med | 2022 |
| 34996412 | Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. | BMC Cancer | 2022 |
| 34663578 | Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. | Gut | 2022 |
| 32897581 | Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. | Clin Pharmacol Ther | 2021 |
| 33549263 | COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. | Mayo Clin Proc | 2021 |
| 34282303 | Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. | Genet Med | 2021 |
| 33428770 | Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. | Clin Pharmacol Ther | 2021 |
| 33299147 | Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. | Genet Med | 2021 |
| 32985005 | DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. | Pharmacotherapy | 2020 |
| 31928229 | Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial. | Circ Genom Precis Med | 2020 |
| 31837229 | Translational Informatics Connects Real-World Information to Knowledge in an Increasingly Data-Driven World. | Clin Pharmacol Ther | 2020 |
| 33315113 | Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. | JAMA Netw Open | 2020 |
| 32747766 | Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. | Genet Med | 2020 |
| 32678355 | Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. | Genet Med | 2020 |
| 30608869 | Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016. | Circ Cardiovasc Interv | 2019 |
| 31617441 | Activation of HCAR2 by niacin: benefits beyond lipid lowering. | Pharmacogenomics | 2019 |
| 31462078 | Gut Microbiome and Response to Cardiovascular Drugs. | Circ Genom Precis Med | 2019 |
| 31393222 | Early adoption of pharmacogenetic testing for veterans prescribed psychotropic medications. | Pharmacogenomics | 2019 |
| 31173123 | Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. | JAMA Netw Open | 2019 |
| 29280137 | Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. | Clin Pharmacol Ther | 2018 |
| 29799992 | Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. | JAMA Intern Med | 2018 |
| 30371334 | Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. | J Am Heart Assoc | 2018 |
| 30354338 | SLCO1B1 and Statin Therapy. | Circ Genom Precis Med | 2018 |
| 29488032 | Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. | Curr Treat Options Cardiovasc Med | 2018 |
| 29650772 | Branched-Chain Amino Acids: The Metabolic Link Between Type 2 Diabetes Mellitus and Cardiovascular Disease? | Circ Genom Precis Med | 2018 |
| 28063333 | Development and validation of a liquid chromatography-mass spectrometric assay for simultaneous determination of tacrolimus and 13-O-desmethyl tacrolimus in rat kidney tissue. | J Pharm Biomed Anal | 2017 |
| 28294551 | The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. | Clin Transl Sci | 2017 |
| 28125622 | Expression of Calgranulin Genes S100A8, S100A9 and S100A12 Is Modulated by n-3 PUFA during Inflammation in Adipose Tissue and Mononuclear Cells. | PLoS One | 2017 |
| 28119443 | Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. | J Lipid Res | 2017 |
| 29103068 | Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. | Curr Atheroscler Rep | 2017 |
| 28628560 | Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy. | Pharmacogenet Genomics | 2017 |
| 26990455 | Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. | Am J Transplant | 2016 |
| 29057167 | Pharmacogenetics in Cardiovascular Medicine. | Curr Genet Med Rep | 2016 |
| 27235470 | Systematic Review of Calcineurin Inhibitor Monitoring and Dosing Strategies in Renal Transplantation: Notice of a New Report Funded by the Agency for Healthcare Research and Quality. | Clin Chem | 2016 |
| 25732742 | Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. | Curr Atheroscler Rep | 2015 |
| 24713591 | High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. | Clin Pharmacol Ther | 2014 |